Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000733261 | SCV000861306 | pathogenic | not provided | 2018-05-22 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000156940 | SCV005058728 | pathogenic | Glycogen storage disease, type II | 2024-03-16 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000733261 | SCV005325584 | pathogenic | not provided | 2023-06-26 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 31254424, 23360637, 27927596, 31101460, 31125121, 27344650, 27649523, 30105547, 31342611) |
Fulgent Genetics, |
RCV000156940 | SCV005653235 | pathogenic | Glycogen storage disease, type II | 2024-02-07 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000156940 | SCV005837498 | pathogenic | Glycogen storage disease, type II | 2024-02-24 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Ala694Glyfs*43) in the GAA gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GAA are known to be pathogenic (PMID: 18425781, 22252923). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with Pompe disease (PMID: 27344650). ClinVar contains an entry for this variant (Variation ID: 180143). For these reasons, this variant has been classified as Pathogenic. |
Medical Genetic Department, |
RCV000156940 | SCV000206661 | pathogenic | Glycogen storage disease, type II | no assertion criteria provided | clinical testing |